Accessibility Menu
Innovent Biologics logo

Innovent Biologics(SEHK) 1801

Market CapHK$187.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)+548%
5 Year+56%
1 Year-4%
1 Month+17%
HK$101.20
-2.50%
-2.60Today
Innovent Biologics last closing stock price
MetricPriceDate
Last closeHKD 101.102026-09-01
Innovent Biologics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1%HKD 100.102026-08-25
1 month+16.61%HKD 86.702026-07-31
3 month+31.55%HKD 76.852026-06-03
Year to date+32.59%HKD 76.252025-12-31
1 year-4.08%HKD 105.402025-09-01
3 year+188.03%HKD 35.102023-08-31
5 year+56.26%HKD 64.702021-09-02
Since inception+548.37%HKD 16.582018-10-31

Innovent Biologics Financials at a Glance

Market Cap

HK$187.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥27.01B

Net Income (TTM)

CN¥2.35B

EPS (TTM)

HK$0.78

P/E Ratio

131.97

Dividend

HK$0.00

Beta (Volatility)

-0.05 (Low)

Price

HK$101.20

Volume

3,944,351

Open

HK$103.80

Previous Close

HK$103.80

Daily Range

HK$100.90 - HK$103.80

52-Week Range

HK$69.55 - HK$112.70

Estimated Earnings Date

Mar 31, 2027

1801 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innovent Biologics

Innovent Biologics, Inc. is a leading biopharmaceutical enterprise based in Suzhou, China, established in 2011. The company specializes in the discovery, development, and manufacturing of antibody drug candidates, focusing on oncology, ophthalmology, immunology, and metabolic diseases.

Products and Services
  • Tyvyt (sintilimab) for various cancers
  • Byvasda for multiple malignant tumors
  • Halpryza for non-Hodgkin's lymphoma and chronic lymphocytic leukemia
Growth Outlook
  • Strong pipeline with investigational therapies targeting critical diseases
  • Strategic alliances with major pharmaceutical companies enhance market reach
  • Increasing demand for innovative therapies in the biopharmaceutical sector
Financial Highlights
  • Recent quarterly revenue of 7.09 billion CNY, showing significant growth
  • Trailing twelve months (TTM) gross profit margin at 76.4%, indicating strong profitability
  • Current ratio of 2.62, reflecting solid liquidity position
Innovent Biologics has established itself as a key player in the biopharmaceutical industry, with a diverse portfolio of products and a robust pipeline of investigational therapies. The company's focus on critical therapeutic areas positions it well for future growth, especially as demand for innovative treatments continues to rise. Recent financial performance indicates a strong revenue trajectory, supported by a healthy gross profit margin and liquidity. Strategic partnerships further enhance its market presence, making Innovent Biologics an intriguing option for potential investors interested in the biotechnology sector.
AI Generated • Aug 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

7,502

CEO

De Chao Yu, PhD

Website

www.innoventbio.com

Headquarters

Suzhou, JS 215123, CN

1801 Financials

Key Financial Metrics (TTM)

Gross Margin

80.96%

Operating Margin

12.02%

Net Income Margin

7.80%

Return on Equity

6.06%

Return on Capital

3.31%

Return on Assets

2.92%

Earnings Yield

0.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$187.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.74B

Volume

3.94M

Avg. Volume

14.99M

Financials (TTM)

Gross Profit

CN¥21.34B

Operating Income

CN¥2.60B

EBITDA

CN¥3.29B

Operating Cash Flow

CN¥11.60B

Capital Expenditure

-CN¥535.75M

Free Cash Flow

CN¥11.06B

Cash & ST Invst.

CN¥20.00B

Total Debt

CN¥2.32B

Innovent Biologics Performance Analysis

Innovent Biologics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 5,298,514,9633.0%
20232023-12-31CNY 6,857,694,92129.4%
20242024-12-31CNY 10,215,435,61149.0%
20252025-12-31CNY 14,143,836,48338.5%
Innovent Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3138.4%
Q22025-06-308.8%
Q42025-12-3119.1%
Q22026-06-3019.9%
Innovent Biologics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -1.70-24.7%
20232023-12-31CNY -0.73-57.2%
20242024-12-31CNY -0.06-91.3%
20252025-12-31CNY 0.51N/A
Innovent Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31175.0%
Q22025-06-30172.2%
Q42025-12-31-102.4%
Q22026-06-305862.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥8.50B

+115.0%

Gross Profit

CN¥7.22B

+152.7%

Gross Margin

84.96%

N/A

Market Cap

HK$187.45BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$24.99M

N/A

Employees

7,502

N/A

Net Income

CN¥1.24B

+414.8%

EBITDA

CN¥2.21B

+987.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥20.00B

+131.8%

Total Debt

CN¥2.32B

-30.6%

Accounts Receivable

CN¥1.90B

+39.0%

Inventory

CN¥1.88B

+171.8%

Long Term Debt

CN¥1.78B

-23.7%

Short Term Debt

CN¥551.03M

-45.5%

Return on Assets

2.92%

N/A

Return on Invested Capital

5.80%

N/A

Free Cash Flow

CN¥0.00

+100.0%

Operating Cash Flow

CN¥0.00

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 1801

What is the current price of Innovent Biologics?

Innovent Biologics is trading at HK$101.20 per share.

What is the 52-week range for Innovent Biologics?

Over the past 52 weeks, Innovent Biologics has traded between HK$69.55 and HK$112.70.

How much debt does Innovent Biologics have?

As of the most recent reporting period, Innovent Biologics reported total debt of CN¥3.14B.

How much cash does Innovent Biologics have on hand?

Innovent Biologics reported CN¥11.56B in cash and cash equivalents in its most recent financial results.

What is Innovent Biologics’s dividend yield?

Innovent Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services